Caris Life Sciences Launches ChromoSeq, Ultra-Deep Genome And Transcriptome Test To Streamline Diagnosis Of Myeloid Malignancies

Caris Life Sciences has launched Caris ChromoSeq, an ultra-deep Whole Genome and Transcriptome Sequencing test aimed at improving the diagnosis of myeloid malignancies such as acute myeloid leukemia and myelodysplastic syndromes. This assay offers approximately 250x read depth and 40 million transcriptome reads, streamlining the diagnostic process by consolidating multiple tests into a single report with a turnaround time of seven days. The test is designed to enhance the identification of clinically relevant mutations and support timely clinical decision-making.